Clinical observation of topical steroid for the treatment of chronic rhinosinusitis in Chinese adults.
- Author:
Jie DENG
1
;
Rui XU
;
Ke-jun ZUO
;
Dong CHEN
;
Geng XU
;
Jian-bo SHI
Author Information
- Publication Type:Journal Article
- MeSH: Administration, Intranasal; Adolescent; Adult; Aged; Chronic Disease; Female; Humans; Male; Middle Aged; Sinusitis; drug therapy; Steroids; administration & dosage; adverse effects; therapeutic use; Treatment Outcome; Young Adult
- From: Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2012;47(12):1027-1029
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEThis study was focused on the clinical effects of topical steroid for chronic rhinosinusitis (CRS) in Chinese adults.
METHODSThe CRS patients were randomly selected in the department of otorhinolaryngology, first affiliated hospital of Sun Yat-sen university between november 2010 and December 2011. Thirty-four CRS patients with polyps (CRSwNP) or CRS without polyps (CRSsNP), no prior surgeries were included. These patients were prescribed to use budesonide nasal spay for three months. Evaluation included visual analog score (VAS), sino-nasal outcome test-20(SNOT-20), CT scan (Lund-Mackay score). SPSS 16.0 software was used to analyze the data.
RESULTSFour patients were lost to follow up, while the other 30 patients finished the 3-months' follow up. Except for smelling disturbance which was not statistically changed (t = 0.902, P > 0.05), VAS for nasal blockage (baseline: 4.84 ± 3.15, after treatment: 2.26 ± 2.27), rhinorrhea (baseline: 6.03 ± 2.93, after treatment: 1.96 ± 2.23), headache (baseline: 1.68 ± 2.66, after treatment: 0.42 ± 0.95), facial pressure (baseline: 2.04 ± 2.97, after treatment: 0.58 ± 1.42) and general symptom (baseline: 6.00 ± 2.75, after treatment: 2.71 ± 1.90) were statistically decreased (t value was 4.386, 6.740, 2.445, 2.980, 6.989, respectively, all P < 0.05). VAS of nasal blockage, rhinorrhea and general symptom were statistically decreased after one-month's treatment (all P < 0.05), but no statistical improvements were observed between first, second and the third month (all P > 0.05). SNOT-20 was significantly decreased after treatment (t = 3.687, P < 0.01). 22.2% patients were cured on CT scan.
CONCLUSIONSTopical steroid improves objective symptoms and quality of life in CRS patients. Some of the patients can be cured in CT scores. The symptoms improvements begin from the first month, but do not change during the latter two months.